ReNeuron to Present at 2nd Annual Stem Cell Summit. 14/02/07

Guildford, UK, 12 February 2007: ReNeuron Group plc (LSE: RENE.L) today announces that its Founder and Chief Scientific Officer, Dr. John Sinden, will present an overview of the Company’s leading edge stem cell technologies and programmes at the 2nd Annual Stem Cell Summit being held at the Wyndham at Emerald Plaza San Diego in San Diego, California. The presentation is scheduled for Monday, February 12, 2007 at 2:45 PM PST.

Utilizing its proprietary c-mycER^TAM adult stem cell expansion platform, ReNeuron is developing groundbreaking cell therapy products. The Company is currently focused on cell therapy treatments designed to reverse the effects of major diseases such as stroke, Parkinson’s disease, diabetes and diseases of the retina.

More information about the conference may be found at www.stemcellsummit.com.

Notes to editors

ReNeuron is a leading, UK-based adult stem cell therapy business. It is applying its novel stem cell platform technologies in the development of ground-breaking stem cell therapies to serve significant and unmet or poorly-met clinical needs. ReNeuron has used its c-mycER^TAM technology to generate genetically stable neural stem cell lines. This technology platform has multi-national patent protection and is fully regulated by means of a chemically-induced safety switch. Cell growth can therefore be completely arrested prior to in vivo implantation.

ReNeuron has filed for approval to commence initial clinical studies in the US with its lead ReN001 stem cell therapy for chronic stroke disability. This represents the world’s first such filing concerning a neural stem cell treatment for a major neurological disorder. There are an estimated 50 million stroke survivors worldwide, approximately one half of which are left with permanent disabilities. The annual health and social costs of caring for these patients is estimated to be in excess of £5 billion in the UK and in excess of US$50 billion in the US.

ReNeuron has also generated pre-clinical efficacy data with its ReN005 stem cell therapy for Huntington’s disease, a genetic and fatal neurodegenerative disorder that affects around 1 in 10,000 people. This programme is in pre-clinical development.

In addition to its stroke and Huntington’s disease programmes, ReNeuron is developing stem cell therapies for Parkinson’s disease, Type 1 diabetes and diseases of the retina.

ReNeuron has also leveraged its stem cell technologies into non-therapeutic areas � its ReNcell^TM range of cell lines for use in research and in drug discovery applications in the pharmaceutical industry. ReNeuron’s ReNcell^TM CX and ReNcell^TM VMneural cell lines are marketed worldwide under license by Millipore Corporation.

ReNeuron’s shares are traded on the London AIM market under the symbol RENE.L.

Further information on ReNeuron and its products can be found at www.reneuron.com.

Data sources: UK Stroke Association, American Stroke Association.

Further information

ReNeuron

Financial Dynamics

This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as “should”, “expects”, “estimates”, “believes” or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron’s current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron’s actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.

The terms �ReNeuron’, �the Company’ or �the Group’ used in this statement refer to ReNeuron Group plc and/or its subsidiary undertakings, depending on the context.

Back